- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01261260
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers (Uridine-GABA)
The Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those indicating GABA-ergic effects following 14 day pyrimidine administration, the purpose of this study is to assess our following hypotheses:
- Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase brain GABA levels in a sample of healthy, unmedicated adult males;
- Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase NTP levels in a sample of healthy, unmedicated adult males; and
- Brain GABA levels will be directly correlated to high energy phosphate levels in this sample of healthy, unmedicated adult males.
Study Overview
Detailed Description
Based on prior MRS studies by our group as well as the work of others, we hypothesize that oral administration of uridine will actuate an increase in brain gamma-amino butyric acid (GABA) levels, along with beta-nucleotide triphosphate (ß-NTP) levels, as compared with baseline. Our aim is to investigate this specific neuropharmacological effect and to demonstrate the suitability of a novel magnetic resonance spectroscopy protocol in so doing. Our rationale includes the consideration that the clinical utility of an intervention demonstrably effective in elevating brain GABA and high energy phosphate levels is broad, since lowered GABA and bioenergetic states are associated with a plurality of affective, anxiety, and substance use disorders.
On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those noting GABA-ergic effects of 14 day pyrimidine administration, we hypothesize that an oral dose of 2g of uridine per day for seven days will increase brain GABA levels in a sample of healthy, unmedicated adult males. We also hypothesize that this 2g dose of uridine per day for 7 days will increase ß-NTP levels and, further, that the increase in GABA and high energy phosphate levels will be correlated. Of note, the phosphorylation of glutamic acid decarboxylase by ATP significantly increased the activity of this enzyme, which is reponsable for the synthesis of GABA. This choice of time period will allow a determination of time course to efficacy between the acute and extended ranges, and further, because therapeutic dosage levels of uridine have yet to be established, in this and future studies we hope to determine the optimal dosage at which uridine increases brain GABA and ß-NTP levels.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- McLean Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male
- Age range of 18-60 years
- BMI between 18.5 and 28
- Medication-free
- Capable of providing informed consent
- Non- smoking for a minimum of one year
Exclusion Criteria:
- Meets DSM-IV criteria for any Axis I disorder (past or present)
- Global assessment of functioning (DSM IV TR) less than 50
- Age less than 18 or greater than 60
- BMI lower than 18.5 or higher than 28
- Any history of Alcohol or substance dependence or abuse according to DSM-IV criteria (except for caffeine dependence)
- Any medical condition which in the opinion of the investigator may have an effect on mood symptoms
- Any individual who has a current mood disturbance (as defined by DSM-IV-R criteria)
- Use of cigarettes or other nicotine-containing products
- Allergy or other contraindication to uridine
- Individuals unable to comply with instructions or procedures of study
- History of significant head trauma
- Claustrophobia or other contraindication to MRI (e.g., pacemaker, metal fragments)
- Any illicit substance use in the past thirty days
- Any past treatment for substance abuse
- Any past hospitalization for mental illness.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Uridine
1g BID
|
1 gram tablets BID for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Using MRI and MRS, after uridine administration an increase in brain GABA and NTP levels will be seen and increases in GABA and NTP will be correlated
Time Frame: after 7 days of treatment
|
This choice of time period will allow a determination of time course to efficacy between the acute and extended ranges, and further, because therapeutic dosage levels of uridine have yet to be established, in this and future studies we hope to determine the optimal dosage at which uridine increases brain GABA and ß-NTP levels.
|
after 7 days of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Perry F Renshaw, MD PhD, The Brain Institute, University of Utah
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2005-P-002083-McLean
- 2R01MH058681-04A2 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Subjects
-
AkesoNot yet recruitingHealthy Male Subjects
-
Sunshine Lake Pharma Co., Ltd.Completed
-
RAPT Therapeutics, Inc.Completed
-
AstraZenecaParexelCompletedHealthy Male SubjectsUnited States
-
AstraZenecaParexelCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedHealthy Male SubjectsChina
-
Shanghai Henlius BiotechCompletedHealthy Male SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
Clinical Trials on Uridine
-
Repligen CorporationCompletedBipolar DepressionUnited States
-
VA Office of Research and DevelopmentActive, not recruitingSuicidal IdeationUnited States
-
University of UtahNational Institute of Mental Health (NIMH)Completed
-
National Center for Research Resources (NCRR)University of California, San DiegoCompleted
-
University of UtahThe Depressive and Bipolar Disorder Alternative Treatment FoundationCompletedBipolar Disorder | Bipolar Depression | Manic DepressionUnited States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Wellstat TherapeuticsApproved for marketing
-
Wellstat TherapeuticsCompletedHereditary Orotic AciduriaUnited States
-
Merck Sharp & Dohme LLCCompleted
-
National Center for Complementary and Integrative...CompletedHIV Infections | Insulin Resistance | HyperlactatemiaUnited States